Brought to you by 
Synlogic gets $40mm via Series B
17 Feb 2016
Executive Summary
Synlogic Inc. (creating therapeutics based on its synthetic biology and microbiome platforms) raised $40mm in its Series B financing led by OrbiMed HealthCare Fund Management, which adds a board member and was joined by other new backer Deerfield Management and returning shareholders Atlas Venture and New Enterprise Associates. Proceeds will help support development of its urea cycle disorder and phenylketonuria programs, which are expected to enter the clinic in 2017. The financing comes just one week after Synlogic teamed up with AbbVie, the biotech's first corporate partner.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Synlogic gets $40mm via Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice